KALV vs. AMRX, OGN, MIRM, APLS, DNLI, VCEL, NAMS, AAPG, KYMR, and BHVN
Should you be buying KalVista Pharmaceuticals stock or one of its competitors? The main competitors of KalVista Pharmaceuticals include Amneal Pharmaceuticals (AMRX), Organon & Co. (OGN), Mirum Pharmaceuticals (MIRM), Apellis Pharmaceuticals (APLS), Denali Therapeutics (DNLI), Vericel (VCEL), NewAmsterdam Pharma (NAMS), Ascentage Pharma Group International (AAPG), Kymera Therapeutics (KYMR), and Biohaven (BHVN). These companies are all part of the "pharmaceutical products" industry.
KalVista Pharmaceuticals vs.
KalVista Pharmaceuticals (NASDAQ:KALV) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings, community ranking and institutional ownership.
KalVista Pharmaceuticals currently has a consensus target price of $24.83, suggesting a potential upside of 109.21%. Amneal Pharmaceuticals has a consensus target price of $11.50, suggesting a potential upside of 58.18%. Given KalVista Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe KalVista Pharmaceuticals is more favorable than Amneal Pharmaceuticals.
31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 10.5% of KalVista Pharmaceuticals shares are owned by insiders. Comparatively, 26.6% of Amneal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
KalVista Pharmaceuticals has a beta of 0.05, indicating that its share price is 95% less volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500.
KalVista Pharmaceuticals received 329 more outperform votes than Amneal Pharmaceuticals when rated by MarketBeat users. However, 95.24% of users gave Amneal Pharmaceuticals an outperform vote while only 75.05% of users gave KalVista Pharmaceuticals an outperform vote.
KalVista Pharmaceuticals has a net margin of 0.00% compared to Amneal Pharmaceuticals' net margin of -6.88%. KalVista Pharmaceuticals' return on equity of -103.92% beat Amneal Pharmaceuticals' return on equity.
In the previous week, Amneal Pharmaceuticals had 3 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 11 mentions for Amneal Pharmaceuticals and 8 mentions for KalVista Pharmaceuticals. KalVista Pharmaceuticals' average media sentiment score of 1.12 beat Amneal Pharmaceuticals' score of 0.97 indicating that KalVista Pharmaceuticals is being referred to more favorably in the media.
Amneal Pharmaceuticals has higher revenue and earnings than KalVista Pharmaceuticals. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
KalVista Pharmaceuticals and Amneal Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.
Get KalVista Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
KalVista Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:KALV) was last updated on 5/21/2025 by MarketBeat.com Staff
Buy KALV Stock Free KALV Stock Alerts